GlassScriptPhysician profile
Chad Alan Glazer
NPI 1609915503
$1,447.16
in general payments reported to CMS, 2019-2025
13 companies · $22.93 in 2025
The $22.93 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $143 · 2022: $216 · 2023: $59.78 · 2024: $144 · 2025: $22.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $226.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $650.00 | 2019 | |
| Stryker Corporation | $266.76 | 2019-2022 | |
| Optinose US, INC. | $243.12 | 2019-2024 | |
| Galderma Laboratories, L.P. | $52.09 | 2019-2023 | |
| Convatec INC. | $41.02 | 2024 | |
| Medtronic, INC. | $38.97 | 2024 | Nuvent |
| Aerin Medical INC. | $37.81 | 2019 | |
| Braintree Laboratories, INC. | $25.54 | 2024 | Sutab, Suflave |
| Organogenesis INC. | $23.94 | 2024 | |
| Ethicon US, LLC | $22.93 | 2025 | Ethicon, Vistaseal |
| Regeneron Healthcare Solutions, INC. | $16.25 | 2019 | |
| Acclarent, INC | $15.98 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Glazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.